Table 1

Patients and clinical specimens

RA 1RA 2RA 3RA 4RA 5
HLA phenotypesA2/A26A24/A33A24A31/A33A26/A33
B35/B61B54/B70B51B44/B61B54/B7
Cw9Cw1/Cw7Cw1Cw10Cw10
DR8/DR9DR4DR4/DR12DR4/DR9DR1/DR4
(DRB11-1500803/0901)(DRB11-1500401/0405)(DRB11-1500403/1201)(DRB11-1500405/0901)(DRB11-1500101/0405)
DQ6/DQ9DQ7/DQ4DQ7/DQ8DQ4/DQ9DQ4/DQ5
(DQA11-1500103/03)(DQA11-15003)(DQA11-15003/05)(DQA11-15003)(DQA11-15003/0101=0104)
(DQB11-15003032/0601)(DQB11-1500301/0401)(DQB11-1500301/0302)(DQB11-15003032/0401)(DQB11-1500401/0501)
(DPB11-1500501)(DPB11-1500201/0501)(DPB11-1500301)(DPB11-1500201/0501)(DPB11-1500401/0501)
StageIVIVIVIVIV
Disease duration (y)142418818
ESR (mm 1st h)41202111077
CRP (mg/dl)2.50.41.2117.6
RF (U)27053<202846
Examined jointsleft ankleright MPright MPleft kneeleft knee
right ankleright kneeright elbowright wristright knee
left PIP
left elbow
  • 1-150 In each patient, synovial tissue samples were simultaneously obtained from above joints by therapeutic multiple synovectomy.